Spiro-oxindole MDM2 antagonists
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
1. A compound having Formula I:
wherein:
R 1a , R 1b , R 1c , and R 1d are independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, alkoxy, aryloxy, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted cycloalkenyl, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, and sulfonamido;
R 2 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
R 3a is halo;
R 3b is halo; or
R 3a and R 3b taken together form a 3- to 9-membered optionally substituted cycloalkyl or a 3- to 9-membered optionally substituted heterocyclo;
E is selected from the group consisting of —OR 26a and —NR 26b R 26c ;
R 26a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
R 26b is selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl;
R 26c is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, aralkyl, and —SO 2 R 5b ; or
R 26b and R 26c taken together form a 4- to 9-membered optionally substituted heterocyclo;
X is selected from the group consisting of O, S, and NR′;
Y is selected from the group consisting of O, S, and NR″;
R′ is selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, and optionally substituted cycloalkyl;
R″ is selected from the group consisting of hydrogen, optionally substituted alkyl, aralkyl, and optionally substituted cycloalkyl; and
represents a single or a double bond,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 having Formula III:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 having Formula VI:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 2 having Formula XVI:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein:
E is —NR 26b R 26c ;
R 2 is optionally substituted aryl;
R 26b is hydrogen; and
X and Y are NH,
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 , wherein R 3a and R 3b taken together form a 4- to 8-membered optionally substituted cycloalkyl, or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein R 2 is optionally substituted aryl having Formula R 2 -1:
wherein R 25a , R 25b , R 25c , R 25d , and R 25e are each independently selected from the group consisting of hydrogen, halogen, hydroxy, nitro, amino, cyano, alkoxy, alkyl, or haloalkyl,
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 having Formula XXVII:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 having Formula XXVIII:
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 , wherein R 26c is optionally substituted cycloalkyl, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 10 , wherein R 26c is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 9 , wherein R 26c is optionally substituted phenyl, or a pharmaceutically acceptable salt thereof.
13. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
14. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , wherein E is —OR 26a , or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A method of treating a patient comprising administering to the patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the patient has colon cancer or osteosarcoma.
18. A kit comprising a compound of claim 1 , or a pharmaceutically acceptable salt, thereof, and instructions for administering the compound to a patient having colon cancer or osteosarcoma.
19. A method of preparing a compound having Formula XVI:
comprising:
a) allowing a compound of claim 3 to isomerize; and
b) isolating the compound having Formula XVI substantially free from the compound of claim 3 ,
wherein X and Y are NH.